Mutant prevention concentration of tigecycline for carbapenem-susceptible and-resistant Acinetobacter baumannii

Journal of Antibiotics

Volumn 63, Issue 1, 2010, Pages 29-31

  Cui, Jun Chang ^a   Liu, You Ning ^a   Chen, Liang An ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Acinetobacter baumannii; Mutant prevention concentration; Propensity for selection of resistance; Resistance; Tigecycline

Indexed keywords

CARBAPENEM; TIGECYCLINE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM MUTANT; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; CARBAPENEMS; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; MUTATION;

ACINETOBACTER BAUMANNII;

EID: 76449087003     PISSN: 00218820     EISSN: None     Source Type: Journal    
DOI: 10.1038/ja.2009.111     Document Type: Article

References (19)

1. Cisneros, J. M. et al. Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features. Clin. Infect. Dis. 22, 1026-1032 (1996).
2. Valencia, R. et al. Nosocomial outbreak of infection with pan-drug-resistant Acinetobacter baumannii in a tertiary care university hospital. Infect. Control Hosp. Epidemiol. 30, 257-263 (2009).
3. Zong, Z., Lü, X., Valenzuela, J. K., Partridge, S. R. & Iredell, J. An outbreak of carbapenem-resistant Acinetobacter baumannii producing OXA-23 carbapenemase in western China. Int. J. Antimicrob. Agents. 31, 50-54 (2008).
4. Wang, Y. & Xu, Y. CHINET surveillance of antimicrobial resistance among A. baumannii isolates in China during 2004-2005. Chin. J. Infect. Chemother. 7, 279-282 (2007). (Pubitemid 47323439)
5. Hoban, D. J., Bouchillon, S. K. & Dowzicky, M. J. Antimicrobial susceptibility of extendedspectrum beta-lactamase producers and multidrug-resistant Acinetobacter baumannii throughout the United States and comparative in vitro activity of tigecycline, a new glycylcycline antimicrobial. Diagn. Microbiol. Infect. Dis. 57, 423-428 (2007).
6. Souli,M.et al. In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, Gram-negative and Gram-positive clinical isolates from Greek hospitals. Antimicrob. Agents Chemother. 50, 3166-3169 (2006).
7. Anthony,K.B. et al. Clinical and microbiological outcomes of serious infections with multidrug-resistant Gram-negative organisms treated with tigecycline. Clin. Infect. Dis. 46, 567-570 (2008).
8. Schafer, J. J., Goff, D. A., Stevenson, K. B. & Mangino, J. E. Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrugresistant Acinetobacter baumannii. Pharmacotherapy 27, 980-987 (2007).
9. Reid, G. E., Grim, S. A., Aldeza, C. A., Janda, W. M. & Clark, N. M. Rapid development of Acinetobacter baumannii resistance to tigecycline. Pharmacotherapy 27, 1198-1201 (2007).
10. Zhao, X. & Drlica, K. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin. Infect. Dis. 33 (Suppl. 3), S147-S156 (2001).
11. Blondeau, J. M., Zhao, X., Hansen, G. & Drlica, K. Mutant prevention concentration of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45, 433-438 (2001).
12. Drlica, K., Zhao, X., Blondeau, J. & Hesje, C. Low correlation between MIC and mutant prevention concentration. Antimicrob. Agents Chemother. 50, 403-404 (2006).
13. Smith, H. J., Nichol, K. A., Hoban, D. J. & Zhanel, G. G. Stretching the mutant prevention concentration (MPC) beyond its limits. J. Antimicrob. Chemother. 51, 1323-1325 (2003).
14. Zhao, X. Clarification of MPC and the mutant selection window concept. J. Antimicrob. Chemother. 52, 731 (2003).
15. Conte Jr., J. E., Golden, J. A., Kelly, M. G. & Zurlinden, E. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int. J. Antimicrob. Agents 25, 523-529 (2005).
16. Sun, H. K. et al. Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations. Antimicrob. Agents Chemother. 49, 1629-1632 (2005).
17. Crandon, J. L., Kim, A. & Nicolau, D. P. Comparison of tigecycline penetration into the epithelial lining fluid of infected and uninfected murine lungs. J. Antimicrob. Chemother. 64, 837-839 (2009).
18. Cui, J. et al. The mutant selection window in rabbits infected with Staphylococcus aureus. J. Infect. Dis. 194, 1601-1608 (2006).
19. Ruzin, A., Keeney, D. & Bradford, P. A. AdeABC multidrug efflux pump is associated with decreased susceptibility to tigecycline in Acinetobacter calcoaceticus- Acinetobacter baumannii complex. J. Antimicrob. Chemother. 59, 1001-1004 (2007).